Growth and Differentiation Advantages of CD4+OX40+ T Cells from Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 3, 2008, Pages 268-281

  Shindo, Takero ^a   Ishikawa, Takayuki ^a   Fukunaga, Akiko ^a   Hori, Toshiyuki ^a   Uchiyama, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Allogeneic hematopoietic stem cell transplantation; CD4 T cell; Chronic graft versus host disease (GVHD); OX40

Indexed keywords

BUSULFAN; CD134 ANTIGEN; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; HOMING RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 7; MELPHALAN; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENOLEUKODYSTROPHY; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTATION; APLASTIC ANEMIA; ARTICLE; CELL GROWTH; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MALE; MEMORY T LYMPHOCYTE; MYELODYSPLASTIC SYNDROME; MYELOMA; MYELOPROLIFERATIVE DISORDER; REDUCED INTENSITY CONDITIONING; T CELL LEUKEMIA; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; WHOLE BODY RADIATION;

ADULT; AGED; ANTIGEN PRESENTATION; CD4 LYMPHOCYTE COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC CAPPING; IMMUNOLOGIC MEMORY; INTERLEUKIN-2; INTERLEUKIN-7; LYMPH NODES; MALE; MIDDLE AGED; RECEPTORS, OX40; SIGNAL TRANSDUCTION; TH1 CELLS; TH2 CELLS; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; TUMOR CELLS, CULTURED;

EID: 38949184873     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.12.004     Document Type: Article

References (66)

1. Lee S.J., Vogelsang G., and Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 9 (2003) 215-233
2. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 (1999) 412-415
3. Higman M.A., and Vogelsang G.B. Chronic graft versus host disease. Br J Haematol 125 (2004) 435-454
4. Champlin R.E., Passweg J.R., Zhang M.J., et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95 (2000) 3996-4003
5. Ho V.T., and Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98 (2001) 3192-3204
6. Mavroudis D.A., Dermime S., Molldrem J., et al. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol 101 (1998) 565-570
7. van Dijk A.M., Kessler F.L., Stadhouders-Keet S.A., Verdonck L.F., de Gast G.C., and Otten H.G. Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease. Br J Haematol 107 (1999) 169-175
8. Andre-Schmutz I., Le Deist F., Hacein-Bey-Abina S., et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 360 (2002) 130-137
9. Perreault C., Decary F., Brochu S., Gyger M., Belanger R., and Roy D. Minor histocompatibility antigens. Blood 76 (1990) 1269-1280
10. Vogelsang G.B. How I treat chronic graft-versus-host disease. Blood 97 (2001) 1196-1201
11. Pavletic S.Z., Carter S.L., Kernan N.A., et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 106 (2005) 3308-3313
12. Sakoda Y., Hashimoto D., Asakura S., et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 109 (2007) 1756-1764
13. Latza U., Durkop H., Schnittger S., et al. The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur J Immunol 24 (1994) 677-683
14. Sugamura K., Ishii N., and Weinberg A.D. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 4 (2004) 420-431
15. Stuber E., Neurath M., Calderhead D., Fell H.P., and Strober W. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2 (1995) 507-521
16. Weinberg A.D., Wegmann K.W., Funatake C., and Whitham R.H. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 162 (1999) 1818-1826
17. Ohshima Y., Tanaka Y., Tozawa H., Takahashi Y., Maliszewski C., and Delespesse G. Expression and function of OX40 ligand on human dendritic cells. J Immunol 159 (1997) 3838-3848
18. Baum P.R., Gayle III R.B., Ramsdell F., et al. Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J 13 (1994) 3992-4001
19. Gramaglia I., Weinberg A.D., Lemon M., and Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 161 (1998) 6510-6517
20. Rogers P.R., Song J., Gramaglia I., Killeen N., and Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15 (2001) 445-455
21. Godfrey W.R., Fagnoni F.F., Harara M.A., Buck D., and Engleman E.G. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med 180 (1994) 757-762
22. Maxwell J.R., Weinberg A., Prell R.A., and Vella A.T. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 164 (2000) 107-112
23. Gramaglia I., Jember A., Pippig S.D., Weinberg A.D., Killeen N., and Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 165 (2000) 3043-3050
24. Jember A.G., Zuberi R., Liu F.T., and Croft M. Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. J Exp Mede 193 (2001) 387-392
25. Weinberg A.D., Bourdette D.N., Sullivan T.J., et al. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med 2 (1996) 183-189
26. Yoshioka T., Nakajima A., Akiba H., et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 30 (2000) 2815-2823
27. Salek-Ardakani S., Song J., Halteman B.S., et al. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med 198 (2003) 315-324
28. Higgins L.M., McDonald S.A., Whittle N., Crockett N., Shields J.G., and MacDonald T.T. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol 162 (1999) 486-493
29. Tsukada N., Akiba H., Kobata T., Aizawa Y., Yagita H., and Okumura K. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood 95 (2000) 2434-2439
30. Blazar B.R., Sharpe A.H., Chen A.I., et al. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood 101 (2003) 3741-3748
31. Buenafe A.C., Weinberg A.D., Culbertson N.E., Vandenbark A.A., and Offner H. V beta CDR3 motifs associated with BP recognition are enriched in OX-40+ spinal cord T cells of Lewis rats with EAE. J Neurosci Res 44 (1996) 562-567
32. Tittle T.V., Weinberg A.D., Steinkeler C.N., and Maziarz R.T. Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. Blood 89 (1997) 4652-4658
33. Kotani A., Ishikawa T., Matsumura Y., et al. Correlation of peripheral blood OX40+(CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation. Blood 98 (2001) 3162-3164
34. Hitomi T., Mezaki T., Tsujii T., et al. Improvement of central motor conduction after bone marrow transplantation in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry 74 (2003) 373-375
35. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
36. Imura A., Hori T., Imada K., et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 183 (1996) 2185-2195
37. Gavin M.A., Clarke S.R., Negrou E., Gallegos A., and Rudensky A. Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol 3 (2002) 33-41
38. McHugh R.S., Whitters M.J., Piccirillo C.A., et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16 (2002) 311-323
39. Takeda I., Ine S., Killeen N., et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 172 (2004) 3580-3589
40. Valzasina B., Guiducci C., Dislich H., Killeen N., Weinberg A.D., and Colombo M.P. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105 (2005) 2845-2851
41. Streeter P.R., Zhang X., Tittle T.V., Schon C.N., Weinberg A.D., and Maziarz R.T. CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease. Biol Blood Marrow Transplant 10 (2004) 298-309
42. Seddiki N., Santner-Nanan B., Martinson J., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203 (2006) 1693-1700
43. Fry T.J., and Mackall C.L. Interleukin-7: from bench to clinic. Blood 99 (2002) 3892-3904
44. Surh C.D., Boyman O., Purton J.F., and Sprent J. Homeostasis of memory T cells. Immunol Rev 211 (2006) 154-163
45. Jung T., Schauer U., Heusser C., Neumann C., and Rieger C. Detection of intracellular cytokines by flowcytometry. J Immunol Methods 159 (1993) 197-207
46. Sallusto F., Lenig D., Forster R., Lipp M., and Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401 (1999) 708-712
47. Lanzavecchia A., and Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2 (2002) 982-987
48. Sallusto F., Geginat J., and Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22 (2004) 745-763
49. Stuber E., and Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 183 (1996) 979-989
50. Kotani A., Hori T., Fujita T., et al. Involvement of OX40 ligand(+) mast cells in chronic GVHD after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2007)
51. Alpdogan O., Schmaltz C., Muriglan S.J., et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood 98 (2001) 2256-2265
52. Bolotin E., Smogorzewska M., Smith S., Widmer M., and Weinberg K. Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood 88 (1996) 1887-1894
53. Gendelman M., Hecht T., Logan B., Vodanovic-Jankovic S., Komorowski R., and Drobyski W.R. Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease. J Immunol 172 (2004) 3328-3336
54. Sinha M.L., Fry T.J., Fowler D.H., Miller G., and Mackall C.L. Interleukin 7 worsens graft-versus-host disease. Blood 100 (2002) 2642-2649
55. Napolitano L.A., Grand R.M., Deeks S.G., et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implication for T-cell homeostasis. Nat Med 7 (2001) 73-79
56. Chung B., Dupl E.P., Min D., Barsky L., Smiley N., and Weinberg K.I. Prevention of graft-versus-host disease by anti-IL-7Ralpha antibody. Blood 110 (2007) 2803-2810
57. Codarri L., Vallotton L., Ciuffreda D., et al. Expansion and tissue infiltration of an allospecific CD4+CD25+CD45RO+IL-7Ralphahigh cell population in solid organ transplant recipients. J Exp Med 204 (2007) 1533-1541
58. Kawamata S., Hori T., Imura A., Takaori-Kondo A., and Uchiyama T. Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation. J Biol Chem 273 (1998) 5808-5814
59. Takaori-Kondo A., Hori T., Fukunaga K., Morita R., Kawamata S., and Uchiyama T. Both amino- and carboxyl-terminal domains of TRAF3 negatively regulate NF-kappaB activation induced by OX40 signaling. Biochem Biophys Res Commun 272 (2000) 856-863
60. Endl J., Rosinger S., Schwarz B., et al. Coexpression of CD25 and OX40 (CD134) receptors delineates autoreactive T-cells in type 1 diabetes. Diabetes 55 (2006) 50-60
61. Ito T., Wang Y.H., Duramad O., et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 202 (2005) 1213-1223
62. Bolotin E., Annett G., Parkman G., and Weinberg K. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant 23 (1999) 783-788
63. Saparov A., Wagner F.H., Zheng R., et al. Interleukin-2 expression by a subpopulation of primary T cells is linked to enhanced memory/effector function. Immunity 11 (1999) 271-280
64. Dooms H., Kahn E., Knoechel B., and Abbas A.K. IL-2 induces a competitive survival advantage in T lymphocytes. J Immunol 172 (2004) 5973-5979
65. Wysocki C.A., Panoskaltsis-Mortari A., Blazar B.R., and Serody J.S. Leukocyte migration and graft-versus-host disease. Blood 105 (2005) 4191-4199
66. Beilhack A., Schulz S., Baker J., et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 106 (2005) 1113-1122